title: Respiratory Tract Infection and Risk of Hospitalization in Children with Congenital Heart Defects During Season and Off-Season: A Swedish National Study.
abstract: Respiratory tract infections (RTI) are common among young children, and congenital heart defect (CHD) is a risk factor for severe illness and hospitalization. This study aims to assess the relative risk of hospitalization due to RTI in winter and summer seasons for different types of CHD. All children born in Sweden and under the age of two, in 2006-2011, were included. Heart defects were grouped according to type. Hospitalization rates for respiratory syncytial virus (RSV) infection and RTI in general were retrieved from the national inpatient registry. The relative risk of hospitalization was calculated by comparing each subgroup to other types of CHD and otherwise healthy children. The relative risk of hospitalization was increased for all CHD subgroups, and there was a greater increase in risk in summer for the most severe CHD. This included RSV infection, as well as RTI in general. The risk of hospitalization due to RTI is greater for CHD children. Prophylactic treatment with palivizumab, given to prevent severe RSV illness, is only recommended during winter. We argue that information to healthcare staff and parents should include how the risk of severe infectious respiratory tract illnesses, RSV and others, is present all year round for children with CHD.
authors.affiliation: Department of Clinical Sciences, Paediatrics, Umeå University, Umeå, Sweden. elinkgranbom@gmail.com.|Unit of Research, Education and Development, Östersund Hospital, Östersund, Sweden. elinkgranbom@gmail.com.
authors.forename: Elin
authors.initials: E
authors.lastname: Granbom
authors.affiliation: Pediatric Heart Center, Lund University and Linköping University, Lund, Linköping, Sweden.
authors.forename: Eva
authors.initials: E
authors.lastname: Fernlund
authors.affiliation: Department of Cardiology at the Queen Silvias Children's Hospital, Sahlgrenska University Hospital, Gothenburg, Sweden.
authors.forename: Jan
authors.initials: J
authors.lastname: Sunnegårdh
authors.affiliation: Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden.
authors.forename: Bo
authors.initials: B
authors.lastname: Lundell
authors.affiliation: Department of Clinical Sciences, Paediatrics, Umeå University, Umeå, Sweden.|Unit of Research, Education and Development, Östersund Hospital, Östersund, Sweden.
authors.forename: Estelle
authors.initials: E
authors.lastname: Naumburg
mesh_terms: D000911:Antibodies, Monoclonal; D000998:Antiviral Agents; D002648:Child; D006330:Heart Defects, Congenital; D006760:Hospitalization; D006801:Humans; D007223:Infant; D018357:Respiratory Syncytial Virus Infections; D012141:Respiratory Tract Infections; D012307:Risk Factors; D012621:Seasons; D013548:Sweden
chemical_list: D000911:Antibodies, Monoclonal; D000998:Antiviral Agents
keywords: Congenital heart defect (CHD); Immunoprophylaxis; Palivizumab; Respiratory syncytial virus; Respiratory tract infection